• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, November 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Masterswitch discovered in body's immune system

Bioengineer by Bioengineer
February 11, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Scientists have discovered a critical part of the body’s immune system with potentially major implications for the treatment of some of the most devastating diseases affecting humans.

Professor Graham Lord, from The University of Manchester, led the study, which could translate into treatments for autoimmune diseases including Cancer, Diabetes, Multiple Sclerosis and Crohn’s Disease within a few years.

It is published in the Journal of Clinical Investigation today.

The discovery of the molecular pathway regulated by a tiny molecule – known as microRNA-142 – is a major advance in our understanding of the immune system.

The 10-year-study found that microRNA-142 controls Regulatory T cells, which modulate the immune system and prevent autoimmune disease. It is, they found, the most highly expressed regulator in the immune system.

Professor Lord, led the research while at Kings College London in collaboration with Professor Richard Jenner at UCL.

And according to Professor Lord, the discovery could be translated into a viable drug treatment within a few years.

He said: “Autoimmune diseases often target people in the prime of their life creating a significant socio-economic burden on them. Sometimes, the effect can be devastating, causing terrible hardship and suffering.

“But these findings represent a significant step forward in the understanding of the immune system and we believe many people worldwide may benefit.”

If the activity of Regulatory T cells is too low, this can cause other immune cells to attack our own body tissues. If these Regulatory T cells are too active, this leads to suppression of immune responses and can allow cancers to evade the immune system.

So being able to control them is a major step forward in our ability to control- and harness – the therapeutic power of the immune system.

Professor Richard Jenner from UCL, who led the computational side of the project, said that: “We were able to trace the molecular fingerprints of this molecule across other genes to determine how it acted as such a critical regulator.”

Professor Lord, now Vice President and Dean of the Faculty of Biology, Medicine and Health at The University of Manchester, added: “Scientists over the past decade or so have developed therapies which are able to modulate different pathways of the immune system. We hope that this new discovery will lead to the development of new ways to treat autoimmunity, infectious diseases and cancer and we are incredibly excited about where this may lead.”

###

NOTES FOR EDITORS

Professor Lord is available for comment

An embargoed copy of the paper ‘microRNA-142-mediated repression of phosphodiesterase 3B critically regulates peripheral immune tolerance’ is available.

For media enquiries contact:

Mike Addelman

Media Relations Officer

Faculty of Biology, Medicine and Health

University of Manchester

0161 275 2111

07717 881567

[email protected]

Media Contact
Mike Addelman
[email protected]
07-717-881-567

Tags: BiochemistryBiologycancerCell BiologyGeneticsMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Immune Checkpoint Inhibition Shifts Failure Patterns in Lung Cancer

November 2, 2025

Comparing Immune Responses: Rituximab vs. Obinutuzumab in Follicular Lymphoma

November 1, 2025

Revolutionary ARDitox Uncovers Cross-Reactive TCR Epitopes

November 1, 2025

New Shear Wave Insights for Healthy Pediatric Livers

November 1, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1295 shares
    Share 517 Tweet 323
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    312 shares
    Share 125 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    203 shares
    Share 81 Tweet 51
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    137 shares
    Share 55 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Surviving Post-NICU: Caring for Complex Infants

Eggplant Genotypes’ Resistance Mechanisms Against Leucinodes orbonalis

Unraveling CpG Island Methylation Through Read Bias Analysis

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.